AbbVie (ABBV) to Acquire Apogee Therapeutics
AbbVie and Apogee Therapeutics said June 22 they signed a definitive agreement for AbbVie to acquire Apogee. AbbVie will pay $135.11 per share in cash, valuing Apogee at about $10.9 billion. Both boards approved unanimously, and AbbVie expects closing in fiscal Q3 2026, subject to shareholder and regulatory approvals.
How this was made
The 30-second read
Why it matters
The deal provides a concrete cash offer price ($135.11/share) and total equity value (~$10.9B), plus a targeted closing window (fiscal Q3 2026) with customary regulatory and shareholder approvals.
Market read
This is a definitive M&A catalyst with explicit consideration and timing, driving immediate repricing and deal-spread dynamics for both stocks.
What to watch
Closing is targeted for fiscal Q3 2026 and is contingent on regulatory approvals and Apogee shareholder approval—deal-spread trading should price these timelines and risks.
Background
AbbVie and Apogee entered a definitive agreement for AbbVie to acquire Apogee’s clinical-stage immunology/inflammatory pipeline, including asthma and atopic dermatitis.
Ticker impact
AbbVie agreed to acquire Apogee Therapeutics for $135.11/share in cash, valuing Apogee at ~$10.9B and targeting a fiscal Q3 2026 close.
Near-term upside bias on deal premium expectations, with volatility around regulatory and shareholder-approval risk.
The article discloses concrete deal terms (per-share price, total equity value) and a targeted closing quarter, which typically drives immediate repricing and then risk-premium adjustments.
Apogee Therapeutics will be acquired by AbbVie for $135.11/share in cash, with unanimous board approval and regulatory/stockholder approvals required.
Likely positive reaction toward the offer price, with spread compression subject to deal-completion probability.
The article provides the definitive agreement terms and per-share consideration, which is the primary driver for target-stock repricing.
Market effects
Reinforces consolidation in immunology/inflammatory and respiratory-adjacent pharma pipelines, potentially affecting deal expectations for similar mid-cap biopharma.
Primarily impacts US large-cap and mid-cap pharma sentiment; limited direct regional spillover beyond US-listed peers.
Could influence global pharma M&A appetite for immunology/respiratory assets, though the article is US-focused.
Counterpoint
The headline upside may be offset by execution and regulatory uncertainty; the market may fade the initial premium if approval risk rises.
Key entities
- public_companyAbbVie Inc.
Acquirer; will pay $135.11/share in cash to acquire Apogee and expand immunology/respiratory pipeline presence.
- public_companyApogee Therapeutics
Target; will be acquired for $135.11/share in cash, with unanimous board approval and required regulatory/stockholder approvals.
